Benzimidazole compounds that are vitronectin receptor antagonists

A compound having the formula:

• wherein n, p, q and r are each independently selected from 0 or 1;
• a, b, c, and d each independently represents a carbon or nitrogen atom, with the proviso that no more than two of a, b, c, and d are nitrogen atoms;
• Y and Y1 each independently represents 1-4 optional substituents selected from alkyl, alkoxy, halo, —CF3, and —C(O)OH;
• R1 is H, alkyl, aryl, aralkyl, arylcycloalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, heteroaralkyl, cycloalkylalkyl, heterocycloalkylalkyl, —NHRA, —NHC(O)RA, —NHSO2RA, NHC(O)NHRA or —NHC(O)ORA, R1 being optionally substituted by 1-3 groups selected from halo, alkyl, —CF3, —CN, —ORB, —SRB, —CO2RB, —C(O)RB, —OC(O)RB, —OC(O)ORB and —SO2RB, and RA and RB are independently selected from H, alkyl, aryl, aralkyl, arylcycloalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, heteroaralkyl, cycloalkylalkyl and heterocycloalkylalkyl, with the proviso that when R1 is alkyl, R1 is not substituted with halo, the proviso that when R1 is —NHSO2RA or —NHC(O)ORA, RA is not H, and the proviso that for —SO2RB or —OC(O)ORB, RB is not H;
• R2 is H, alkyl, aryl, aralkyl, arylcycloalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, heteroaralkyl, cycloalkylalkyl, or heterocycloalkylalkyl, R2 being optionally substituted by 1-3 groups selected from halo, alkyl, —CF3, —CN, —ORC, —SRC, —CO2RC, —C(O)RC, —OC(O)RC, —OC(O)ORC and —SO2RC, wherein RC is selected from H, alkyl, aryl, aralkyl, arylcycloalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, heteroaralkyl, cycloalkylalkyl and heterocycloalkylalkyl, with the proviso that when R2 is alkyl, R2 is not substituted with halo, and the proviso that for —SO2RC or —OC(O)ORC, RC is not H;
• R3 is heterocycloalkylalkyl, heterocycloalkyl, —C(O)RD, —SO2RE, —C(O)NRFRG, —C(O)NRFSO2RE, or —C(═S)NRFRG, wherein RD, RE, RF and RG are independently selected from H, alkyl, aryl, aralkyl, arylcycloalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl and heterocycloalkylalkyl, or RF and RG taken together complete a 5-7 member ring containing 0 to 1 oxygen or sulfur atoms, and 1 to 2 nitrogen atoms, R3 being optionally substituted by 1-3 groups selected from halo, alkyl, —CF3, —CN, —ORH, —SRH, —CO2RH, —C(O)RH, —OC(O)RH, —OC(O)ORH, —SO2RH and —NRH RH, wherein RH is selected from H, alkyl, aryl, aralkyl, arylcycloalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, heteroaralkyl, cycloalkylalkyl and heterocycloalkylalkyl, with the proviso that when R3 is alkyl, R3 is not substituted with halo, the proviso that when R3 is —SO2RE or —CO(O)RD, RD and RE are not H, and the proviso that for —SO2RH or —OC(O)ORH, RH is not H;
• R4 is H, alkyl, aralkyl, arylcycloalkyl, cycloalkylalkyl, heterocycloalkylalkyl, heteroaralkyl, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, R4 being optionally substituted by 1-3 groups selected from halo, alkyl, —CF3, —CN, —ORJ, —SRJ, —CO2RJ, —C(O)RJ, —OC(O)RJ, —OC(O)ORJ and —SO2RJ, wherein RJ is selected from H, alkyl, aryl, aralkyl, arylcycloalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, heteroaralkyl, cycloalkylalkyl and heterocycloalkylalkyl, with the proviso that when R4 is alkyl, R4 is not substituted with halo, and the proviso that for —SO2RJ or —OC(O)ORJ, RJ is not H;
• R5, R6, R7, R8, R9, R10, R11 and R12 are independently selected from H and C1-C3 alkyl;
• and wherein
• are positioned meta or para relative to each other;
• or a biolabile ester thereof, or a pharmaceutically acceptable salt thereof.